Trial Profile
A Multicenter Clinical Trial to Evaluate Quality of Life in Patients With Type 2 Diabetes Before and After Changing Therapy to a Combination of Insulin Glargine and Oral Antidiabetic Drugs in a Real Life Situation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Antihyperglycaemics; Insulin suspension isophane
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 05 Jun 2009 Actual initiation date changed from Aug 2005 to Oct 2005 as reported by ClinicalTrials.gov.
- 29 Sep 2008 Additional trial identifier Eudract2005-000959-15 reported by ClinicalTrials.gov.
- 29 Sep 2008 Planned number of patients changed from 40 to 26 as reported by ClinicalTrials.gov.